Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43597
UPID:
SPY2_HUMAN
Alternative names:
-
Alternative UPACC:
O43597; B2R9J9; Q5T6Z7
Background:
Protein sprouty homolog 2 plays a pivotal role in cellular processes by acting as an antagonist of fibroblast growth factor (FGF) pathways. This inhibition is crucial for modulating various developmental processes, including retinal lens fiber differentiation, limb bud outgrowth, and respiratory organogenesis. Additionally, it plays a role in inhibiting TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells and prevents CBL/C-CBL-mediated EGFR ubiquitination, highlighting its significance in cellular signaling pathways.
Therapeutic significance:
Given its involvement in IgA nephropathy 3, a condition characterized by renal insufficiency progressing to end-stage renal disease, Protein sprouty homolog 2 is a target of interest for therapeutic intervention. Understanding its function and the genetic variants affecting it opens doors to developing strategies aimed at mitigating disease progression and improving patient outcomes.